Welcome to our dedicated page for Arvinas news (Ticker: ARVN), a resource for investors and traders seeking the latest updates and insights on Arvinas stock.
Arvinas Inc operates at the forefront of targeted protein degradation, a novel therapeutic approach that generates distinct news catalysts compared to traditional drug developers. The company's PROTAC platform, which induces complete protein degradation rather than temporary inhibition, produces news around clinical trial results, regulatory milestones, and scientific presentations that demonstrate this innovative mechanism in action.
News coverage for Arvinas typically centers on clinical data releases from its oncology programs, particularly trials evaluating protein degraders in hormone-dependent cancers. Each data readout provides insights into whether targeted protein degradation delivers on its theoretical advantages over conventional inhibitors, including deeper responses, longer durability, and activity in resistant disease. These clinical updates often include pharmacodynamic data confirming actual protein degradation in patients, a unique aspect of PROTAC development that validates the mechanism alongside efficacy measures.
Regulatory developments represent another key news category, including FDA interactions, clinical trial initiations, and submission milestones. For a company pioneering a new drug class, regulatory feedback shapes both individual program trajectories and the broader acceptance of protein degradation as a viable therapeutic modality. Scientific presentations at major oncology and drug discovery conferences also generate newsworthy content, as Arvinas shares preclinical data on pipeline expansion and mechanistic insights that inform the investment thesis around PROTAC technology.
Partnership announcements and collaborations provide additional news flow, signaling both industry validation of the platform and potential revenue streams. These deals often involve major pharmaceutical companies seeking to apply targeted protein degradation to their own proprietary targets, expanding the technology's reach beyond Arvinas' wholly-owned programs. Financial results and corporate developments round out the news landscape, offering insights into cash runway, program prioritization, and strategic direction as the company advances its clinical-stage pipeline toward potential commercialization.
Arvinas, a clinical-stage biotechnology company focused on targeted protein degradation, will have its Chief Scientific Officer Ian Taylor and Chief Financial Officer Sean Cassidy participate in a fireside chat during the Stifel Targeted Oncology Day on April 26, 2023, at 11:30 a.m. ET. The event will be available via a live audio webcast, accessible from Arvinas' website. The company aims to develop therapies that degrade disease-causing proteins and currently has three investigational clinical-stage programs. These programs include bavdegalutamide and ARV-766 for prostate cancer treatment, as well as ARV-471 for breast cancer. The company uses its proprietary PROTAC Discovery Engine to engineer targeted protein degraders.
Arvinas, Inc. (Nasdaq: ARVN) has appointed Kelly Page as Senior Vice President, Global Head of Oncology Strategy and Program Leadership. With over 25 years in the pharmaceutical industry, including significant experience in oncology from her previous role at AstraZeneca, Ms. Page is expected to enhance Arvinas' Executive Committee. Her expertise spans research to commercialization, which may strengthen the company’s focus on developing targeted protein degradation therapeutics. This leadership change aligns with Arvinas' commitment to advancing its clinical-stage oncology programs, including those for prostate and breast cancers.
Arvinas, a clinical-stage biotechnology company focused on targeted protein degradation, will participate in two upcoming investor conferences. The Cowen 43rd Annual Health Care Conference is scheduled for March 6, featuring a fireside chat with Chief Medical Officer Ron Peck and Senior VP Randy Teel. A live audio webcast will be available here. The Oppenheimer 33rd Annual Healthcare Conference will be held on March 13, with the same speakers and similar webcast availability here.
Arvinas, a clinical-stage biotechnology company, reported significant developments in its drug pipeline, specifically ARV-471, for treating ER+/HER2- metastatic breast cancer. The company initiated a Phase 3 trial for this monotherapy and presented Phase 2 data from the VERITAC trial. Arvinas gained FDA alignment for a Phase 3 trial combining ARV-471 with palbociclib, set to start in 2H 2023. Financially, Arvinas recorded revenue of $131.4 million for 2022, up from $53.6 million in 2021, largely due to the ARV-471 collaboration with Pfizer. However, the company also posted a net loss of $282.5 million and research expenses rose to $315 million.
Arvinas, a clinical-stage biotechnology company focused on targeted protein degradation, announced participation in three investor conferences. The events include the Guggenheim Oncology Conference on February 9, featuring a fireside chat with Chief Medical Officer Ron Peck and CFO Sean Cassidy. The SVB Leerink Global Healthcare Conference on February 16 will include Ron Peck and Randy Teel, Senior VP of Corporate Development. Finally, the Citi Oncology Leadership Summit on February 23 will feature Chief Scientific Officer Ian Taylor. Live audio webcasts will be available for each presentation on the company’s website.
Arvinas, a clinical-stage biotechnology company, will present an overview at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 1:30 p.m. PT in San Francisco. CEO John Houston will lead the presentation, focusing on the company's innovative approach to targeted protein degradation. Arvinas utilizes its proprietary PROTAC® Discovery Engine to develop therapies aimed at devastating diseases, including investigational programs for metastatic prostate and breast cancer. A live audio webcast of the presentation will be available online.
Arvinas, a clinical-stage biotechnology firm, announces the resignation of Brad Margus from its Board, with Everett Cunningham appointed as his replacement. Margus was a valued member of the Audit Committee, contributing significantly to Arvinas' development. Cunningham brings over 25 years of experience in pharmaceuticals, previously holding key roles at Exact Sciences and GE Healthcare. With expertise in commercialization and a strong background in medical services, Cunningham is expected to enhance Arvinas’ transition into late-stage development and improve patient outcomes.
ARV-471, a novel PROTAC® estrogen receptor degrader, exhibits promising activity in patients with advanced ER+/HER2- breast cancer, achieving a median progression-free survival of 3.7 months overall and 5.7 months in patients with ESR1 mutant tumors. A clinical benefit rate of 38% was recorded in a heavily pre-treated cohort. Initial results from the VERITAC trial support the initiation of two Phase 3 trials. The study emphasizes ARV-471's favorable tolerability profile and potential as a new standard of care, with plans to initiate pivotal trials in late 2022 and early 2023.
FAQ
What is the current stock price of Arvinas (ARVN)?
What is the market cap of Arvinas (ARVN)?
